Bruce A. Andrien, Jr.,Douglas L. Sheridan,Paul P. Tamburini
申请号：
US14641026
公开号：
US09079949B1
申请日:
2015.03.06
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
